SEC Filing Summary: AVROBIO, Inc. (AVRO)
Business Context and Reporting Period
This Form 8-K was filed by AVROBIO, Inc. on February 27, 2023, reporting an event that occurred on February 23, 2023. The filing addresses the company's compliance status with The Nasdaq Stock Market listing requirements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock price.
Material Changes
The primary material change is the resolution of a listing deficiency. Previously, on October 4, 2022, Nasdaq notified the company that its common stock failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days. On February 23, 2023, Nasdaq confirmed that the stock closed at or above $1.00 per share for 10 consecutive business days (February 8–22, 2023), thereby restoring compliance.
Guidance, Outlook, and Risks
Management commentary is limited to the confirmation of regained compliance. The risk of delisting due to the Minimum Bid Price Requirement has been removed as the matter is now closed. No financial guidance or other contingencies are disclosed in this filing.
Investor Verification Checklist
- Verify the current trading price of AVRO common stock to ensure it remains above the $1.00 threshold.
- Review the company's most recent 10-K or 10-Q for financial health metrics not included in this 8-K.
- Confirm no other pending Nasdaq deficiency notices exist for the company.